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Abstract
Background: A recently published systematic review indicated superiority of duodenum-preserving techniques when 
compared with pancreatoduodenectomy, for the treatment of patients with chronic pancreatitis in the head of the 
gland. A multicentre randomised trial to confirm these results is needed.
Methods/Design: ChroPac aims to investigate differences in quality of life, mortality and morbidity during 24 months 
after surgery (duodenum-preserving pancreatic head resection versus pancreatoduodenectomy) in patients with 
chronic pancreatitis of the pancreatic head.
ChroPac is a randomised, controlled, observer and patient blinded multicentre surgical trial with two parallel
comparison groups. The primary outcome measure will be the average quality of life during 24 months after surgery.
Statistical analysis is based on the intention-to-treat population. Analysis of covariance will be applied for the
intervention group comparison adjusting for age, centre and quality of life before surgery. Level of significance is set
at 5% (two-sided) and sample size (n = 100 per group) is determined to assure a power of 90%.
Discussion: The ChroPac trial will explore important outcomes from different perspectives (e.g. surgeon, patient, 
health care system). Its pragmatic approach promises high external validity allowing a comprehensive evaluation of 
the surgical strategy for treatment of patients with chronic pancreatitis.
Trial registration: Controlled-trials.com ISRCTN38973832
Background
Rationale of the trial
Chronic pancreatitis (CP) is defined as a continuous
inflammatory process causing permanent structural
damage ultimately resulting in impairment of the gland's
exocrine and endocrine function [1,2]. The most impor-
tant causative agent is alcohol. Patients with CP who
present with inflammatory pancreatic head enlargement,
commonly require pancreatic head resection due to
development of local complications (e. g. stenosis of the
common bile duct and/or main pancreatic duct, duode-
nal obstruction, compression of retropancreatic vessels),
suspicion of malignancy, and most commonly intractable
pain [3,4]. Pancreatoduodenectomy (PD), i.e. the classical
Whipple (CW) and subsequently the pylorus-preserving
Whipple (PPW) procedure has served as primary surgical
procedures for removal of the pancreatic head in patients
with CP and pancreatic head enlargement for many years.
However, PD is reported to have unsatisfactory outcome
in terms of late morbidity; including high incidence of
postoperative diabetes mellitus of up to 48%, attributed to
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the extensive resection of the duodenum and a larger por-
tion of the pancreas [5]. In order to preserve the duode-
num and limit resection of the pancreatic tissue to a
minimum, the duodenum-preserving pancreatic head
resection (DPPHR) was introduced by H. G. Beger in
1972 [6,7]. While the Beger procedure selectively
removes the pancreatic head, two modifications of this
procedure were developed in order to prevent dissection
of the pancreas above the portal and superior mesenteric
vein, a potential source of haemorrhage, particularly in
case of portal hypertension: The Frey procedure consists
of a local resection of the pancreatic head, which is com-
bined with lateral pancreaticojejunostomy; in the Berne
procedure the pancreatic head is resected subtotally, leav-
ing a narrow layer of pancreatic tissue towards the duo-
denum and the retropancreatic vessels [4,8,9] (Figure 1).
Preliminary data
A recently published randomised trial demonstrated
superiority of surgical treatment (i. e. pancreaticoje-
junostomy) as compared with endoscopic drainage in
patients with chronic pancreatitis and a distal pancre-
atic duct obstruction without an inflammatory mass,
respectively [10]. Moreover, an up-to-date systematic
review with meta-analysis indicated superiority of duo-
denum-preserving pancreatic head resection (DPPHR)
compared with pancreatoduodenectomy (PD) in terms
of several intra- (blood replacement) and postoperative
(exocrine insufficiency, length of hospital stay, weight
gain and occupational rehabilitation) outcome parame-
ters as well as quality of life (QoL) [11]. However, this
potential superiority of DPPHR is currently based on
small hypothesis driven clinical trials performed in a
single-institution setting and may be distorted by as well
random error due to small sample sizes, as systematic
sources of bias such as allocation concealment, stan-
dardization of study interventions, definition of out-
come parameters, consistency of follow-up, and blinded
outcome assessment. Large multicenter randomised tri-
als comparing the two main strategies (DPPHR vs. PD)
focussing on both the surgeons and patients perspec-
tives are still missing.
Objective
ChroPac aims to investigate differences in QoL during 24
months after surgery of DPPHR versus PD and mortality
as well as general and pancreas-associated postoperative
morbidity.
Trial locations
ChroPac will be performed in thirteen trial sites with
expertise for pancreatic surgery. Most of the participants
were involved in a former multicentre-trial surgical trial
for pancreatic left resection (DISPACT Trial, ISRCTN
18452029) carried out by the Study Centre of the German
Surgical Society (SDGC). Thus the ChroPac trial group
consists of international pancreatic surgeons at high-vol-
ume centres who also have expertise in trial conduction.
Figure 1 Techniques of pancreatoduodenectomy and duodenum-preserving pancreatic head resection (DPPHR). (A) Classical Whipple pro-
cedure after resection and reconstruction with pancreaticojejunostomy, bilio-digestive anastomosis and gastrojejunostomy. (B) DPPHR according to 
Beger: Dissection of the pancreas above the portal vein, escavation of the pancreatic head and incision of the common bile duct. Reconstruction s 
accomplished by two pancreaticojejunostomies (corpus and pancreatic head). (C) DPPHR, Berne modification: Excavation of the pancreatic head and 
incision of the common bile duct without dissection of the pancreas above the portal vein. Reconstruction is accomplished by one single side-to-side 
pancreatcojejunostomy. (D) DPPHR, Frey modification: circumscripted excavation of the pancreatic head and longitudinal incision of the pancreatic 
duct. Reconstruction is accomplished by pancreaticojejunostomy.Diener et al. Trials 2010, 11:47
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Methods/Design
Trial population and eligibility criteria
All patients scheduled for primary elective surgery for
chronic head-pancreatitis will be eligible, assuming their
ability to understand the character and individual conse-
quences of participation as well as written informed con-
sent. Patients participating in another interventional trial
with potential interference of intervention (e.g. trials
evaluating alternative perioperative analgetic regimens,
application of octreotide etc.) and outcome (e.g. trials
focussing on QoL) will be excluded.
Sample size
A total of 200 patients will be randomised and included in
the analysis.
Type of Trial
Randomised, controlled, observer and patient blinded
multicentre surgical trial with two parallel comparison
groups.
Recruitment and trial timeline
13 centres with high-level expertise for pancreatic sur-
gery will contribute to recruitment of study patients. The
duration of the trial for each participant is expected to be
about 2 years. The duration of the overall trial is expected
to be 5 years, including prearrangement and analysis.
Recruitment of participants started in April 2009. The
process of the trial conduct is illustrated in Figure 2.
Randomisation
In order to achieve comparable intervention-groups,
patients will be allocated concealed by preoperative ran-
domisation at the day of surgery using a centralised web
based tool http://www.randomizer.at. Block randomisa-
tion will be performed for each centre to achieve equal
group sizes per centre.
Blinding




Any surgical technique that removes inflamed pancreatic
tissue of the head without resection of the duodenum
(e.g. Begers, Frey or Berne procedure).
Control-Intervention
PPW or CW.
The procedures in both groups can be chosen accord-
ing to preference of the surgeon which is based on his/her
personal knowledge, skills and mainly the anatomical sit-
uation of the patient, since ChroPac aims to compare
general surgical strategies rather than to compare certain
modifications of the surgical procedure. Each participat-
ing centre performs the procedure according to local
standards and according to the anatomical situation.
The schedule of trial interventions is presented in Table 1.
Risks
No additional risks for study patients are awaited, since
all surgical procedures carried out within ChroPac repre-
sent clinically established standard methods of treatment
of chronic pancreatitis.
Outcomes
The primary outcome measure of this trial is the average
QoL during 24 months after surgery, measured 6, 12 and
24 months after surgery by the EORTC QLQ-C30 scale
„physical functioning“ (PF-2). Secondary outcomes of:
mortality, general (wound infection, pulmonary infec-
tion) and pancreas-associated postoperative morbidity
(pancreatic fistula, delayed gastric emptying), operation
time, intraoperative blood loss, initial postoperative hos-
pital stay, reoperation, hospital stay related due to chronic
pancreatitis within 24 months after randomisation,
weight gain, development of exocrine insufficiency and
new onset of diabetes mellitus will be assessed (Table 2).
All outcome variables will be evaluated according to
internationally accepted standards and scoring systems if
available, i.e. the consensus definitions for pancreatic fis-
tula and delayed gastric emptying of the International
Study Group of Pancreatic Surgery (ISGPS) [12,13].
Figure 2 ChroPac study flow.
Screening: patients admitted with chronic pancreatitis  
n = 400 
Compliant patients fulfilling inclusion criteria with  
informed consent n = 200 
Randomisation: day of surgery prior to opening of  
the abdominal cavity 
Duodenum preserving 
pancreatic head  
resection  n = 100 
Discharge day 
  n = 50 no informed consent 
n = 50 no compliance 
n = 100 fulfilling exclusion criteria 
V 4 
   V 2 
V 3 
V 1 
QOL 6 months 
QOL 12 months 
QOL 24 months 
V 5 
V 6 
To be analysed: n=100 
Pancreatico- 
duodenectomy 
n = 100 
Discharge day 
QOL 6 months 
QOL 12 months 
QOL 24 months 
To be analysed: n=100 Diener et al. Trials 2010, 11:47
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Data management
All protocol-required information for the clinical data
collected during the trial must be entered by the investi-
gator, or by a designated representative, in the eCRF. The
investigator is responsible for ensuring that all sections of
the eCRF are completed correctly and that entries can be
verified against source data. Any entry and correction in
the Remote Data Entry System will be recorded automat-
ically in an audit file. Once the documentation of a
patient is completed and checked for plausibility the
investigator is asked to date and sign it via electronic
identification. Documentation of quality of life question-
naires will be done on paperbased CRFs.
Double data entry will be accomplished in order to
ensure completeness, validity and plausibility of trial
data.
Safety evaluation and reporting of adverse events
Analysis of safety related data is performed with respect
to frequency of serious adverse events, frequency of seri-
ous adverse events stratified by causality and frequency of
morbidity in both treatment groups.
From the day the patient has signed informed consent
until the regular end of trial at 24 months follow-up or
until premature withdrawal of the patient, all serious
adverse events will be documented on a "serious adverse
event form" available in the investigator site file. A serious
adverse event will be defined as an event, that results in
death, is immediately life-threatening, requires or pro-
longs hospitalization or results in persistent or significant
disability or incapacity. Serious adverse events will be
classified to intensity (mild, moderate, severe), outcome
(ongoing, recovered completely, recovered with sequelae,
death, unknown) and causality (unrelated; possibly, prob-
ably or definitely related to trial intervention; not assess-
able). The assessment is based on surgical findings and
the clinical course of the patient. It needs to be done by
the investigators in the participating trial centres. They
will be furnished with written recommendations on how
to assess causality with trial intervention within the
ChroPac trial.
Serious adverse events have to be reported by the
attending physician to the principal investigator within
24 hours after the SAE becomes known.
Statistical methods
Sample size calculation
The sample size calculation is based on the primary out-
come and the primary analysis for the intention-to-treat
population. The prior assumption based on the evalua-
tion of 2 clinical trials is a mean intervention group dif-
ference of 10% for the EORTC QLQ-C30 scale "physical
functioning" (range 0 to 100) with an estimated standard
deviation of 20% 24 months after the surgical interven-
tion [14,15].
With a two-sided level of significance α = 5% and a
power of 1-β = 90%, a sample size of 86 patients per inter-
vention group is required to detect this difference with a
two-sided Student's t-test. It is assumed that an applica-
tion of an analysis of covariance in the evaluation will
lead to a reduction of the standard deviation. F urther -
more, using the average of the EORTC QLQ-C30 scale
"physical functioning" measured after 6,12 and 24 months
instead of the value 24 months after the surgical interven-























Assessment of secondary 
outcome measures and safety
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Quality of Life X X X X
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Table 2: Summary and definitions of secondary outcomes
Summary and definitions secondary outcomes
Mortality Death due to any cause at any time during the follow-up period including reason.
General morbidity
▪ Wound infection Surgical site infections will be assessed at discharge and 6 months after surgery, divided into 
superficial and deep incisional surgical site infection according to the Center for Disease 
Control and Prevention definition [22].
▪ Pulmonary infection Post-Op-Pulmonary infection will be assessed, at discharge and 6 months and is defined 
according to local standards:
Infection of the lung with either evidence of increased infection parameters (CRP > 2 mg/dl 
and/or leukocytes > 10 0000/ml) which are not caused by a different pathologic process or 
evidence of pulmonary infiltration in the chest x-ray, requiring antibiotic therapy.
Pancreas associated postoperative morbidity
▪ Postoperative Pancreatic fistula [12] Any abnormal communication between the pancreatic ductal epithelium and another 
epithelial surface containing pancreas-derived, enzyme-rich fluid.
It should satisfy the following criteria:
• output through an operatively placed drain or a subsequently placed percutaneous 
drain of any measurable volume of drain fluid
• on or after postoperative day 3
• amylase content in fluid greater than three times the upper normal serum value.
Since only longstanding observation will confirm the diagnosis, it is necessary to distinguish 
and to grade the POPF as grades A, B and C after clinical recovery is complete.
Grade A:
• Without clinical impact
• Oral nutrition
• No antibiotics
• No somatostatin analogues
• No peripancreatic fluid collection
• No delay in hospital discharge
Grade B:
• Clinically relevant
• Partial/total parenteral/enteral nutrition
• Peripancreatic collection possible
• Abdominal pain, fever, and/or leucocytosis possible
• Antibiotics and somatostatin analogues may be necessary
• Delay in hospital discharge or readmission may be required
Grade C:
• Clinical stability maybe borderline
• Treatment in an intensive care unit in many cases
• Total parenteral/enteral nutrition
• Intravenous antibiotics and somatostatin analogues necessary
• Worrisome peripancreatic fluid collection that requires percutaneous drainage
• Extended hospital stay
• Often associated complications and postoperative mortality possible
▪ Delayed gastric emptying [13] Delayed gastric emptying represents the inability to return to a standard diet by the end of 
the first postoperative week and includes prolonged nasogastric intubation of the patient. 
Three different grades (A, B, and C) were defined based on the impact of the clinical course 
and on postoperative management.Diener et al. Trials 2010, 11:47
http://www.trialsjournal.com/content/11/1/47
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tion will presumably sharpen and stabilize the extent of
the intervention group difference as also differences
between the intervention groups that occur earlier after
the surgery are taken into account. It can therefore be
expected that this will increase the actual power of the
trial as compared with the power calculated on the basis
of the above-mentioned assumptions.
To compensate a potential loss in power caused by
withdrawals, the sample size is increased by 15% and
hence a total of 200 patients will be randomised.
Analysis
The confirmatory analysis is performed for the intention-
to-treat (ITT) population.
The two-sided null-hypothesis for the primary out-
come measure states that both surgical interventions lead
to the same expected average QoL scores during 24
months after surgery. This null-hypothesis will be tested
by application of an analysis of covariance that adjusts for
age, centre and EORTC QLQ-C30 scale „physical func-
tioning“ before surgery. Missing values will be replaced
by multiple imputation [16].
Methods of descriptive data analysis will be used for the
secondary outcome measures. Descriptive statistics will
be calculated according to the scale level of the variables.
Further analyses include the time course of the primary
and secondary outcome measures. Additionally, sensitiv-
ity analyses will be conducted using different patient pop-
ulations (per-protocol population excluding patients with
relevant protocol violations), different imputation tech-
niques for missing values, and different statistical meth-
ods for taking into account covariates. Graphical
methods including scatter plots and boxplots will be used
to visualize the findings of the trial.
The safety analysis includes calculation of frequencies
and rates of complications and serious adverse events
reported in the two intervention groups. All analyses will
be done using SAS Version 9.1. or higher.
Withdrawals
Patients are free to withdraw trial participation at their
own request at any time and without giving reasons for
their decision. Moreover, the primary investigator can
withdraw study patients, if continuation of the trial would
be detrimental to the patient's well being.
Withdrawals will be documented in the CRF and in the
patient's medical records and all ongoing serious adverse
events have to be followed up.
Data Safety Monitoring Board (DSMB)
In case of any irregularities for example concerning the
frequency or type of serious adverse events reported the
principal investigator will inform the members of the
independent DSMB without delay. At least once every 12
months, the DSMB will receive a written safety report.
The result of the risk/benefit assessment will be reported
to the principal investigator including recommendations
concerning the continuation of the trial (Members of the
DSMB: Gabriele Ihorst, PhD, Centre for Clinical Trials,
University of Freiburg, Germany; Pierluigi Di Sebastiano,
MD, Director General Surgery, San Giovanni Rotondo,
Operation time From skin incision to closure of wound [min].
Blood loss assessed by surgeons and 
anesthesists
Intraoperative blood loss [ml].
Hospital stay
▪ Initial postoperative hospital stay after 
randomization
Day of operation until day of discharge.
▪ Total hospital stay due to chronic pancreatitis 
within 24 months after randomization
Total amount of hospital days after randomization for any treatment due to chronic 
pancreatitis within 24 months.
Reoperation due to recurrence of chronic 
pancreatitis
Any surgical intervention for treatment of the pancreas at any time during the follow-up 
period.
Weight gain Body weight [kg] assessed at all visits.
New onset of diabetes mellitus requiring 
treatment
Any continuous treatment (drugs) of diabetes lasting for 12 months.
Development of exocrine insufficiency 
(continuous supplement of pancreatic enzymes 
necessary)
Any continuous treatment (drugs) of exocrine insufficiency lasting for 12 months.
Table 2: Summary and definitions of secondary outcomes (Continued)Diener et al. Trials 2010, 11:47
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Foggia, Italy; Helmut Witzigmann, Director Surgical
Department Friedrichstadt Hospital, Dresden, Germany).
Stopping guidelines
No interim analysis is planned for ChroPac. The trial can
be prematurely closed by the coordinating investigator in
consultation with the steering committee, the Data Safety
Monitoring Board and the responsible biometrician for
the following reasons:
• The incidence or severity of serious adverse events/
morbidity in this trial indicates a potential health hazard
caused by the trial treatment.
• It appears that patients' enrolment is unsatisfactory
with respect to quality and/or quantity or data recording
is severely inaccurate and/or incomplete.
• External evidence demanding a termination of the
trial.
In case of premature closure, the ethics committee has
to be informed.
Trial organization and administration
Funding
ChroPac is funded by the DFG (Deutsche Forschungsge-
meinschaft/project funding reference number SE 1682/
2-1).
Monitoring
Clinical Monitoring will be performed by an independent
institution already experienced due to the tasks in some
other surgical trials (Coordinating Centre for Clinical Tri-
als, Heidelberg, Germany) [17]. Monitoring procedures
will be adapted to the trials-specific risk for the patients,
interpretation of ICH-GCP (E6) and standard operating
procedures to ensure patients' safety and integrity of the
clinical data, e.g. primary outcome measure in adherence
to study protocol. Prior to the start of the trial all partici-
pating centres will be personally trained and introduced
into all trial-specific procedures during individual on site
initiation visits. Regular on-site monitoring visits are
planned at all sites depending on the recruitment rate and
quality of the data (approximately one visit per site and
year). The investigator must allow the monitor to look at
all essential documents and must provide support at all
times to the monitor. For 10% of all participants a 100%
clinical source data verification for all clinical items is
planned. In addition, all procedures will be predefined in
a trial-specific monitoring manual. Queries of the data
management (e.g. in case of missing values, implausibility
etc.) have to be answered by the investigators contempo-




Before the start of the trial, the trial protocol, informed
consent document and any other trial documents were
submitted to the independent ethics committee on Janu-
ary 30th 2009. Ethics approval was reviewed on April 20th
2009 and finally issued on May 19th 2009.
Good Clinical Practice
The procedures set out in this trial protocol, pertaining to
the conduct, evaluation and documentation of this trial,
are designed to ensure that all persons involved in the
trial abide by Good Clinical Practice and the ethical prin-
ciples described in the current revision of the Declaration
of Helsinki. The trial will be carried out in keeping with
local legal and regulatory requirements.
Registration
The trial protocol was registered http://www.controlled-
trials.com and was given a unique number for a world-
wide identification of this trial (ISRCTN38973832).
Translational research
The basic and clinical research aims to identify parame-
ters which influence the clinical outcome and may be use-
ful for prognostic or therapeutical decision making in
future with main focus on differences between the two
surgical techniques (DPPHR vs. PPW). Serum parame-
ters (20 ml blood) are investigated and pancreatic tissue is
analysed by histology, as well as biochemical and molecu-
lar biological techniques in a standardised fashion. The
molecular alterations are analysed in detail and assessed
for its clinical implications. Important parameters of pan-
creatic tissue in chronic pancreatitis include inflamma-
tion and fibrosis and the correlation to pain and pain
relief: standardised histological reporting of the degree of
inflammation and fibrosis, identification and quantifica-
tion of expression of pancreatic enzyme activation (e.g.
trypsin), cytokines, chemokines, growth factors (e.g.
EGFR, TGF), stellate cells and its mediators, collagens are
performed.
Since pain is the most frequent indication for pancre-
atic surgery, a main focus is the investigation of pancre-
atic and peripancreatic nerves, neurotransmitter, nerve
growth factors, and the correlation of pain, chronic
inflammation and its relief by pancreatic resection.
Potential markers include substance P, NK-1R, CGRP,
VIP, NPY, PACAP, bradykinine, eicosanoids. Diabetes
mellitus (endocrine insufficiency) has major impact on
the long-term outcome of patients with chronic pancrea-
titis. The correlation of endocrine insufficiency and
reduction of endocrine cells and products (insulin, gluca-
gons) in chronic pancreatitis are investigated. Chronic
pancreatitis is a known risk factor for pancreatic cancer
and premalignant lesions can be detected in inflamma-
tory disease. Serum and tissue markers of carcinogenesis
including K-ras, p-53 will be investigated and correlated
with histology, clinical outcome, and surgical techniques
used. All investigations will be performed centralised and
all data stored in a separate database. This will be linkedDiener et al. Trials 2010, 11:47
http://www.trialsjournal.com/content/11/1/47
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to the clinical database to answer the above-mentioned
questions.
Discussion
Surgical treatment of chronic pancreatitis is indicated in
the case of pancreatic head enlargement with local com-
plications (eg, stenosis of the common bile duct and/or
main pancreatic duct, duodenal obstruction, compres-
sion of retropancreatic vessels), suspicion of malignancy,
and most commonly intractable pain [3,4]. Even without
inflammatory mass of the pancreatic head, a recent RCT
demonstrated surgical treatment of being superior as
compared with endoscopic drainage in patients with
chronic pancreatitis and a distal pancreatic duct obstruc-
tion [10].
The preferred surgical treatment of chronic pancreati-
tis has been a focus of studies and debate for decades.
Several modifications of DPPHR were developed in the
last years in order to reduce surgical trauma and com-
pared with PD and PPW in four single centre RCTs for
safety and efficacy. The results have been pooled in a sys-
tematic review and meta-analysis demonstrating a supe-
riority of DPPHR in terms of QoL, exocrine insufficiency,
length of hospital stay, weight gain and occupational
rehabilitation [11].
Although DPPHR is technically demanding these tech-
niques seem to be promising due to lesser operative
trauma and the gastrointestinal and metabolic integrity
by preservation of the duodenum [9]. Therefore, the role
of DPPHR versus PD has to be evaluated now in a large-
scale pragmatic randomised trial to demonstrate the
effectiveness of DPPHR. Consequently, ChroPac was
designed to focus on both the surgeons and patients per-
spectives in the comparison of the two main strategies
(DPPHR vs. PD) (Figure 3).
Strength and limitations
The research question of ChroPac is based on sufficient
pilot data and since further single centre studies would
not be able to strength the external validity, only a multi-
centre trial can demonstrate the superiority of DPPHR
compared with PD in a setting close to daily practice. The
Study Centre of the German Surgical Society (SDGC) as
the coordinating organisation is experienced and has a
proven track record in performing multicentre surgical
trials, which highlight the SDGC's central role in trial
design and administration and only go to strengthen the
feasibility of the proposed trial [18]. An investigators
meeting, which was conducted prior to the randomisa-
tion of the first patient represents strength of the
ChroPac trial: 15 participants of the recruiting depart-
ments met at the SDGC in Heidelberg, Germany for a
two day educational and practical workshop. While
focussing on the explanation of the trials' rationale, surgi-
cal procedures, ethics, data management and monitoring
within ChroPac, all participants attended surgical proce-
dures for chronic pancreatitis on the second day at the
operation theatres at the Department of General, Visceral
and Transplantation Surgery, University of Heidelberg,
Germany. Overall, the theoretical as well as the hands-on
surgical training was highly appreciated and well-rated by
the participants (range 1.3 - 2.6 with possible grades from
1 to 6). Moreover, there was general agreement regarding
the rationale of the trial, primary outcome measure and
feasibility of the trial (range 1.5 - 1.9 with possible grades
from 1 to 4). As a result content, comprehensiveness and
learning effect was rated to be excellent/very good (range
1.5 - 1.6 with possible grades from 1 to 6). Consequently,
ChroPac promises optimal recruitment of study patients
with good data quality by a both expertise and conform
trial group.
However, the design of ChroPac raised some discussion
during the design phase:
Firstly, the choice of the primary efficacy outcome mea-
sure "quality of life" was debated amongst surgeons, clini-
cal investigators and methodological specialists. As a
consequence, QoL will be evaluated by the EORTC QLQ-
C30 subscore "physical functioning", which was validated
and used in prior RCTs. Besides pain, several other
aspects are summarized in this score and assessed from
the patients' point of view, which justifies the validity of
our primary outcome measure. As a secondary outcome
all data of the full EORTC QLQ questionnaire will be col-
lected in order to assess all dimensions of impairments
and QoL.
Secondly, the specific trial design was a matter of
debate. Since RCTs can be performed as efficacy (or
explanatory) as well as effectiveness (or pragmatic) trials,
the question to focus on internal validity (generation of
the allocation sequence; allocation concealment; blind-
ing; intention to treat analysis; complete outcome report-
ing and follow-up etc.) or on external validity
(generalisability) was of major importance. Thus, per-
forming an efficacy trial promises distinct evaluation of
two surgical procedures rather than surgical strategies.
ChroPac as an efficacy trial would have required explic-
itly defined surgical procedures (e.g. Frey versus PPW)
and study patients. However, patients' compliance and
generalisability is known to be low in these study designs
and four single RCTs are already available [19,20]. As a
result of the discussions during the investigator meeting
Figure 3 ChroPac logo.Diener et al. Trials 2010, 11:47
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the participants agreed and support the pragmatic
approach of ChroPac:
Firstly, the available systematic review showed that the
comparison of duodenum-preserving techniques versus
pancreatoduodenectomy is currently hampered by the
methodological weakness of only small available RCTs.
Secondly, focussing on a sufficient sample size and opti-
mal data quality the pragmatic approach with compact
trial data acquisition and reduced study visits accounts
for the compliance of both the investigators and the par-
ticipating study patients. Thirdly, even a pragmatic
approach allows a translational research part for further
investigations of nature and mechanisms of chronic pan-
creatitis. Moreover, ChroPac evaluates a complex inter-
vention and has to consider the expertise of different
surgeons, peri-operative treatment regimens and con-
comitant interventions. Since these varying components
reflect the current state-of-the-art treatment of chronic
pancreatitis in centres of excellence for pancreatic sur-
gery, ChroPac provides the most efficient evaluation of
the present standard.
In summary, the ChroPac-Trial was designed to iden-
tify the best surgical strategy for treatment of chronic
pancreatitis-either duodenum-preserving head resection
or pancreatoduodenectomy. Focussing on a comparison
of a general surgical strategy implies that the ChroPac-
Trial will not be able to identify the best specific surgical
technique in terms of available modifications of either PD
or DPPHR. The aim of the ChroPac-Trial was therefore to
maximize external validity while sustaining acceptable
internal validity, which was accomplished by its prag-
matic approach [21].
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